Dijana Djureinovic

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better”.

A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better

Molecular Cancer(2023)10.1186/s12943-023-01884-x

N/A

0.635DataRank · unranked

14 citations

Sarah A. Weiss, Irina Krykbaeva, Rihao Qu, Ioannis Vathiotis, Myrto Moutafi +18 more

Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti–CTLA-4 in renal cell carcinoma

JCI Insight(2024)10.1172/jci.insight.184545

N/A

0.466DataRank · unranked

14 citations

Dijana Djureinovic, David Su, Lin Zhang, Benjamin Y. Lu, Larisa Kamga +8 more

Peripheral blood immune cell and cytokine profiling of patients receiving corticosteroids for immune checkpoint inhibitor-related adverse events: Steroid dose and duration.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e14694

N/A

0DataRank · unranked

2 citations

David A. Schoenfeld, Dijana Djureinovic, Matthew Austin, Mamie Wang, Rihao Qu +8 more

Melanocortin 1 receptor (MC1R) expression as a marker of progression in melanoma

Research Square(2023)10.21203/rs.3.rs-3314825/v1

N/A

0DataRank · unranked

2 citations

Dijana Djureinovic, David A. Schoenfeld, Bernadette Marquez‐Nostra, Kelly Olino, Lucia B. Jilaveanu +2 more

Data from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1

(2023)10.1158/1078-0432.c.6530444

N/A

0DataRank · unranked

0 citations

Dijana Djureinovic, Shlomit Jessel, Irina Krykbaeva, Lin Zhang, Lucia B. Jilaveanu +17 more

Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma

JCO Precision Oncology(2024)10.1200/po.23.00702

N/A

0DataRank · unranked

12 citations

Dijana Djureinovic, David A. Schoenfeld, Bernadette Marquez‐Nostra, Kelly Olino, Lucia B. Jilaveanu +2 more

GP100 expression is variable in intensity in melanoma

Cancer Immunology Immunotherapy(2024)10.1007/s00262-024-03776-5

N/A

0DataRank · unranked

10 citations

Nitzan Hasson, David Su, Adebowale Adeniran, Keiran S.M. Smalley, Dijana Djureinovic +4 more

Agonistic CD40 Antibodies in Cancer Treatment

Cancers(2021)10.3390/cancers13061302

N/A

0DataRank · unranked

106 citations

Meina Wang, Harriet M. Kluger, Dijana Djureinovic

Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma

JAMA Network Open(2025)10.1001/jamanetworkopen.2025.18906

N/A

0DataRank · unranked

12 citations

Matthew Liu, David Su, Saba Shafi, Ceren Boyacı, Sanna Steen +69 more

Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma

JCI Insight(2023)10.1172/jci.insight.157347

N/A

0DataRank · unranked

39 citations

Jasmine I. Caulfield, Lin Zhang, David A. Schoenfeld, Dijana Djureinovic, Veronica Chiang +6 more